Tom Nolan’s research reviews—24 November 2022

New hope for lipid profile chatLooking for something new to spice up those cholesterol consultations? Lipoprotein(a) might be just what you’re looking for. It’s thought to be a marker of cardiovascular disease and therefore a candidate for new preventive treatments. A phase 2, dose-finding trial examined the effect of olpasiran (which reduces lipoprotein(a) synthesis in the liver) on lipoprotein(a) levels. This small study, which recruited 281 people with established atherosclerotic cardiovascular disease and high lipoprotein(a) levels, did indeed find a dose dependent reduction in lipoprotein(a) levels in those who received olpasiran. But it’s early days: will this reduction translate into clinically meaningful endpoints? Until then, it’s back to the familiar “good and bad cholesterol” and “let’s take a look at your overall risk” chat.N Engl J Med doi:10.1056/NEJMoa2211023Match of the dayThe New England Journal of Medicine gets into the football World Cup spirit with some research from Qatar. Like the…
Read Original Article: Tom Nolan’s research reviews—24 November 2022 »